Biologics CDMOs Biovian and 3P Biopharmaceuticals have combined with the aim of establishing a new pan-European leader in their field.   Backed by their common shareholder, Keensight Capital, the combination of Biovian and 3P further extends the group’s value proposition to address complex customer needs across the entire development cycle. Introducing 3PBiovian The combined Group, named 3PBiovian, will offer end-to-end development and manufacturing services for all protein expression sys...